Table 2. Multivariate analysis of... | American Society of Hematology

Table 2.

Multivariate analysis of patients undergoing HCT for MPN-BP (N = 177)

Variable	n	HR (95% CI)	P
OS
Cytogenetics			.01
Favorable*/intermediate	97	1.00	—
Adverse	67	1.71 (1.21-2.41)	.002
Not tested/missing	13	1.27 (0.67-2.39)	.47
Graft source
BM	22	1.00	—
PB	155	0.60 (0.38-0.96)	.03
Relapse
Cytogenetics			.003
Favorable†/intermediate	97	1.00	—
Adverse	67	1.93 (1.32-2.82)	.0007
Not tested/missing	13	1.09 (0.50-2.40)	.82
In vivo T-cell depletion
No	131	1.00	—
Yes	46	0.64 (0.42-0.98)	.04
NRM
Graft source
BM	22	1.00	—
PB	155	0.28 (0.12-0.62)	.002
PFS
Cytogenetics			.003
Favorable†/intermediate	97	1.00	—
Adverse	67	1.78 (1.27-2.50)	.0008
Not tested/missing	13	1.11 (0.58-2.10)	.76
Disease status at HCT
PB/BM blasts <5%	101	1.00	—
Active leukemia	76	1.45 (1.05-2.01)	.02
In vivo T-cell depletion
No	131	1.00	—
Yes	46	0.63 (0.44-0.91)	.01

Variable	n	HR (95% CI)	P
OS
Cytogenetics			.01
Favorable*/intermediate	97	1.00	—
Adverse	67	1.71 (1.21-2.41)	.002
Not tested/missing	13	1.27 (0.67-2.39)	.47
Graft source
BM	22	1.00	—
PB	155	0.60 (0.38-0.96)	.03
Relapse
Cytogenetics			.003
Favorable†/intermediate	97	1.00	—
Adverse	67	1.93 (1.32-2.82)	.0007
Not tested/missing	13	1.09 (0.50-2.40)	.82
In vivo T-cell depletion
No	131	1.00	—
Yes	46	0.64 (0.42-0.98)	.04
NRM
Graft source
BM	22	1.00	—
PB	155	0.28 (0.12-0.62)	.002
PFS
Cytogenetics			.003
Favorable†/intermediate	97	1.00	—
Adverse	67	1.78 (1.27-2.50)	.0008
Not tested/missing	13	1.11 (0.58-2.10)	.76
Disease status at HCT
PB/BM blasts <5%	101	1.00	—
Active leukemia	76	1.45 (1.05-2.01)	.02
In vivo T-cell depletion
No	131	1.00	—
Yes	46	0.63 (0.44-0.91)	.01

Factors tested in multivariate analysis are summarized in the Appendix.

Only one patient had favorable cytogenetics.